Zusammenfassung
Die Pharmakotherapie psychiatrischer Notfallpatienten wird wesentlich von der Akuität, dem Notfallort, der diagnostischen Einschätzung und dem besonderen pharmakologischen Anforderungsprofil der eingesetzten Medikamente bestimmt. Da es keine spezifischen Medikamente gibt, erfolgt die Behandlung syndromal. Hierfür stehen vorrangig Antipsychotika und Benzodiazepine zur Verfügung. Der vorliegende Beitrag gibt einen Überblick über den aktuellen Stand der Behandlungsoptionen für die wichtigsten psychiatrischen Notfallsyndrome, nämlich Unruhezustände, Delir, Katatonie und Stupor, Angst und Panik sowie medikamentös-induzierte Notfälle.
Summary
The pharmacotherapy of psychiatric emergencies is essentially determined by the acuteness, the scene of the emergency, the diagnostic assessment and the special pharmacological profile of the drug used. As there are no specific drugs, syndromic treatment is carried out. For this, primarily antipsychotic drugs and benzodiazepines are available. This article gives an overview of the current state of treatment options for major psychiatric emergency syndromes, namely agitation, delirium, stupor and catatonia, anxiety and panic, as well as drug-induced emergencies.
Literatur
TREC Collaborative Group (2003) Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 327:708–713
Ables AZ, Nagubilli R (2010) Prevention, recognition, and management of serotonin syndrome. Am Fam Physician 81:1139–1142
Alexander J, Tharyan P, Adams C et al (2004) Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. Br J Psychiatry 185:63–69
Allen MH, Currier GW (2004) Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry 26:42–49
Asadollahi S, Heidari K, Hatamabadi H et al (2015) Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol 30:142–150
Babington PW, Spiegel DR (2007) Treatment of catatonia with olanzapine and amantadine. Psychosomatics 48:534–536
Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP (2011) Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Rev Bras Psiquiatr 33:30–39
Barak Y, Mazeh D, Plopski I, Baruch Y (2006) Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia. Am J Geriatr Psychiatry 14:629–633
Barbee JG, Mancuso DM, Freed CR, Todorov AA (1992) Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 149:506–510
Bartels SJ, Horn SD, Smout RJ et al (2003) Agitation and depression in frail nursing home elderly patients with dementia: treatment characteristics and service use. Am J Geriatr Psychiatry 11:231–238
Battaglia J (2005) Pharmacological management of acute agitation. Drugs 65:1207–1222
Battaglia J, Moss S, Rush J et al (1997) Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15:335–340
Belgamwar RB, Fenton M (2005) Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev:CD003729
Belvederi Murri M, Guaglianone A, Bugliani M et al (2015) Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 15:45–62
Bieniek SA, Ownby RL, Penalver A, Dominguez RA (1998) A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 18:57–62
Breier A, Meehan K, Birkett M et al (2002) A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59:441–448
Carroll BT, Goforth HW, Thomas C et al (2007) Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 19:406–412
Cavallazzi R, Saad M, Marik PE (2012) Delirium in the ICU: an overview: Ann Intensive Care 2:49
Chan EW, Taylor DM, Knott JC et al (2013) Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med 61:72–81
Citrome L (2007) Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 68:1876–1885
Citrome L (2012) Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int J Clin Pract 66:318–325
Citrome L, Volavka J, Czobor P et al (2006) Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 67:638–642
Crowner ML, Peric G, Stepcic F, Lee S (2005) Assailant and victim behaviors immediately preceding inpatient assault. Psychiatr Q 76:243–256
Currier GW, Chou JC, Feifel D et al (2004) Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 65:386–394
De Fruyt J, Demyttenaere K (2004) Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. Eur Psychiatry 19:243–249
Di Salvo TG, O’Gara PT (1995) Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 18:285–290
Dorevitch A, Katz N, Zemishlany Z et al (1999) Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 156:142–144
Dosi R, Ambaliya A, Joshi H, Patell R (2014) Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep 2014
Foster S, Kessel J, Berman ME, Simpson GM (1997) Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 12:175–179
Frucht SJ (2014) Treatment of movement disorder emergencies. Neurotherapeutics 11:208–212
Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF (1989) Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation: Am J Psychiatry 146:1598–1601
Gillman PK (2010) Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 25:1780–1790
Goedhard LE, Stolker JJ, Heerdink ER et al (2006) Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. J Clin Psychiatry 67:1013–1024
Gortney JS, Fagan A, Kissack JC (2009) Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 43:785–791
Grover S, Kumar V, Chakrabarti S (2011) Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. J Psychosom Res 71:277–281
Han CS, Kim YK (2004) A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 45:297–301
Hatta K, Takahashi T, Nakamura H et al (2001) The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol 21:257–261
Hovens JE, Dries PJ, Melman CT et al (2005) Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol 19:51–57
Huband N, Ferriter M, Nathan R, Jones H (2010) Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev:CD003499
Huf G, Alexander J, Allen MH, Raveendran NS (2009) Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev:CD005146
Jones RM, Arlidge J, Gillham R et al (2011) Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 198:93–98
Kim SW, Yoo JA, Lee SY et al (2010) Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 25:298–302
Kinon BJ, Stauffer VL, Kollack-Walker S et al (2008) Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 28:601–607
Kirino E (2010) Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clin Schizophr Relat Psychoses 4:185–188
Knott JC, Taylor DM, Castle DJ (2006) Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med 47:61–67
Kropp S, Andreis C, te Wildt B et al (2007) Characteristics of psychiatric patients in the accident and emergency department (ED). Psychiatr Prax 34:72–75
Kwentus J, Riesenberg RA, Marandi M et al (2012) Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 14:31–40
Lee KU, Won WY, Lee HK et al (2005) Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. Int Clin Psychopharmacol 20:311–314
Lesem MD, Tran-Johnson TK, Riesenberg RA et al (2011) Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 198:51–58
Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev:CD005594
Lonergan E, Luxenberg J (2009) Valproate preparations for agitation in dementia. Cochrane Database Syst Rev:CD003945
Marco CA, Vaughan J (2005) Emergency management of agitation in schizophrenia. Am J Emerg Med 23:767–776
Moscovich M, Novak FT, Fernandes AF et al (2011) Neuroleptic malignant syndrome. Arq Neuropsiquiatr 69:751–755
Munhoz RP, Moscovich M, Araujo PD, Teive HA (2012) Movement disorders emergencies: a review. Arq Neuropsiquiatr 70:453–461
Musshoff F, Doberentz E, Madea B (2013) Lethal neuroleptic malignant syndrome due to amisulpride. Forensic Sci Med Pathol 9:218–220
Owen C, Tarantello C, Jones M, Tennant C (1998) Violence and aggression in psychiatric units. Psychiatr Serv 49:1452–1457
Pajonk FG, Schmitt P, Biedler A et al (2008) Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings. Gen Hosp Psychiatry 30:360–366
Pascual JC, Madre M, Soler J et al (2006b) Injectable atypical antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 39:117–118
Patra BN, Khandelwal SK, Sood M (2013) Olanzapine induced neuroleptic malignant syndrome. Indian J Pharmacol 45:98–99
Pelland C, Trudel JF (2009) Atypical antipsychotic efficacy and safety in managing delirium: a systematic review and critical analysis. Psychol Neuropsychiatr Vieil 7:109–119
Peralta V, Campos MS, Jalon EG de, Cuesta MJ (2010) DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res 118:168–175
Perry PJ, Wilborn CA (2012) Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 24:155–162
Powell G, Caan W, Crowe M (1994) What events precede violent incidents in psychiatric hospitals? Br J Psychiatry 165:107–112
Pratts M, Citrome L, Grant W et al (2014) A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 130:61–68
Puffer E, Messer T, Pajonk FG (2012) Psychiatric care in emergency departments. Anaesthesist 61:215–223
Raveendran NS, Tharyan P, Alexander J, Adams CE (2007) Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 335:865
Rocca P, Villari V, Bogetto F (2006) Managing the aggressive and violent patient in the psychiatric emergency. Prog Neuropsychopharmacol Biol Psychiatry 30:586–598
Rortgen D, Schaumberg A, Skorning M et al (2011) Stocked medications in emergency physician-based medical services in Germany. Reality and requirements according to guidelines. Anaesthesist 60:312–324
Satterthwaite TD, Wolf DH, Rosenheck RA et al (2008) A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 69:1869–1879
Schwerthöffer D, Beuys D, Hamann J et al (2015) Versorgung psychiatrischer Notfälle in psychiatrischen Kliniken in Deutschland. Psychiatr Prax. DOI 10.1055/s-0034-1387644
Seitz DP, Adunuri N, Gill SS et al (2011) Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev:CD008191
Skrobik YK, Bergeron N, Dumont M, Gottfried SB (2004) Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 30:444–449
Strawn JR, Keck PE Jr, Caroff SN (2007) Neuroleptic malignant syndrome. Am J Psychiatry 164:870–876
Tardiff K, Sweillam A (1982) Assaultive behavior among chronic inpatients. Am J Psychiatry 139:212–215
Trollor JN, Chen X, Chitty K, Sachdev PS (2012) Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 201:52–56
Trollor JN, Sachdev PS (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 33:650–659
Uguz F, Sonmez EO (2013) Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. Gen Hosp Psychiatry 35:327
Vieweg WV, Wood MA, Fernandez A et al (2009) Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26:997–1012
Villari V, Rocca P, Fonzo V et al (2008) Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry 32:405–413
Wagstaff AJ, Easton J, Scott LJ (2005) Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 19:147–164
Wang HR, Woo YS, Bahk WM (2013) Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci 67:323–331
Wang Y, He R, Zhang H (2012) Case report on clozapine-associated neuroleptic malignant syndrome. Shanghai Arch Psychiatry 24:116–117
Wilson MP, MacDonald K, Vilke GM, Feifel D (2012) A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med 43:790–797
Wilson MP, Minassian A, Bahramzi M et al (2014) Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department. J Emerg Med 46:808–813
Wilson MP, Pepper D, Currier GW et al (2012) The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med 13:26–34
Wright P, Birkett M, David SR et al (2001) Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158:1149–1151
Zeller SL, Rhoades RW (2010) Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clin Ther 32:403–425
Zisselman MH, Jaffe RL (2010) ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 167:127–132
Einhaltung ethischer Richtlinien
Interessenkonflikt. T. Messer für das Jahr 2014: Vortragshonorare und finanzielle Unterstützung bei Kongressen: Lundbeck GmbH, Otsuka, Janssen-Cilag, Trommsdorff. F.-G. Pajonk hat in den letzten 3 Jahren die Fa. Trommsdorff beratend unterstützt und hat bezahlte Vorträge mit Unterstützung der Fa. Trommsdorff gehalten. M.J. Müller hat Reisekostenerstattungen für wissenschaftliche Tagungen, Kongresse oder Fortbildungsveranstaltungen von Servier, Lilly, Lundbeck, Janssen-Cilag und Merz Pharma erhalten, war in einem Advisory Board von Lundbeck, ist im Besitz von Aktien der Firma Novartis und hat Vortragshonorare von Servier und Janssen-Cilag erhalten.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Messer, T., Pajonk, FG. & Müller, M. Pharmakotherapie von psychiatrischen Akut- und Notfallsituationen. Nervenarzt 86, 1097–1110 (2015). https://doi.org/10.1007/s00115-014-4148-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-014-4148-x
Schlüsselwörter
- Notfallmedizin
- Notfallpsychiatrie
- Psychopharmaka
- Verabreichung und Dosierung
- Medikamentenbezogene Begleiterscheinungen und Nebenwirkungen